// App-Quantinova.ai

538 : Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

Researchers

Presenter

  • Filip Van den Bosch

Principal Investigators

  • Louis Bessette

  • Alan Kivitz

  • Yihan Li

  • Alan Friedman

  • Aileen Pangan

  • Heidi Camp

  • Joel Kremer

Medical Centers

  • Charite-University Medicine Berlin, Berlin, Germany

  • Ghent University Hospital, Ghent, Belgium

  • Laval University, Quebec, Quebec, Canada.

  • Altoona Center for Clinical Research, Duncansville, PA

  • AbbVie, Inc., North Chicago, IL

  • AbbVie, Inc., North Chicago, IL

  • Albany Medical Center, Albany, NY

Locations

  • Germany

  • Belgium

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved